Back to today’s briefing

Story perspectives

Novartis Surges with $13.2B Q4 Sales, 22% Income Boost

1/31/2025

29 2

Summary

Story summary

Novartis achieved impressive fourth-quarter sales of $13.2 billion, surpassing estimates by 16%.
Core operating income increased by 22% to $19.5 billion for 2024, fueled by top-performing drugs like Entresto and Kesimpta.
The company anticipates mid- to high-single-digit sales growth for 2025, despite potential patent expirations.
CEO Vas Narasimhan highlighted the benefits of their strategic transformation.

History

Historical Context

Novartis' recent sales surge reflects a strategic shift initiated in 2007, transforming it into a specialty biopharmaceutical company. This echoes Bristol-Myers Squibb's successful pivot in the 2010s, emphasizing innovative therapies amid patent challenges, showcasing how historical transformations shape current market resilience.

1 of 2

Story summary

Novartis achieved impressive fourth-quarter sales of $13.2 billion, surpassing estimates by 16%.
Core operating income increased by 22% to $19.5 billion for 2024, fueled by top-performing drugs like Entresto and Kesimpta.
The company anticipates mid- to high-single-digit sales growth for 2025, despite potential patent expirations.
CEO Vas Narasimhan highlighted the benefits of their strategic transformation.

1 / 2